"Piperazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D010879
|
| MeSH Number(s) |
D03.383.606
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Piperazines".
Below are MeSH descriptors whose meaning is more specific than "Piperazines".
This graph shows the total number of publications written about "Piperazines" by people in this website by year, and whether "Piperazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 3 | 0 | 3 |
| 2002 | 6 | 2 | 8 |
| 2003 | 11 | 5 | 16 |
| 2004 | 5 | 6 | 11 |
| 2005 | 4 | 7 | 11 |
| 2006 | 2 | 5 | 7 |
| 2007 | 8 | 2 | 10 |
| 2008 | 3 | 5 | 8 |
| 2009 | 7 | 7 | 14 |
| 2010 | 8 | 6 | 14 |
| 2011 | 10 | 8 | 18 |
| 2012 | 6 | 4 | 10 |
| 2013 | 5 | 5 | 10 |
| 2014 | 4 | 2 | 6 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 3 | 5 |
| 2017 | 5 | 2 | 7 |
| 2018 | 3 | 4 | 7 |
| 2019 | 6 | 6 | 12 |
| 2020 | 3 | 3 | 6 |
| 2021 | 6 | 6 | 12 |
| 2022 | 0 | 9 | 9 |
| 2023 | 2 | 6 | 8 |
| 2024 | 4 | 4 | 8 |
| 2025 | 2 | 2 | 4 |
| 2026 | 3 | 1 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Piperazines" by people in Profiles.
-
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul; 10(7):e2600456.
-
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. J Clin Oncol. 2026 Mar 10; 44(8):653-661.
-
Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan; 10:e2500716.
-
The Prognostic and Predictive Impact of ctDNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial. Clin Cancer Res. 2026 Jan 06; 32(1):148-158.
-
Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct; 9:e2500649.
-
DGAT1 Inhibition Enhances Olaparib-Induced Lipotoxic Apoptosis in Metastatic Castration-Resistant Prostate Cancer. FASEB J. 2025 Aug 15; 39(15):e70925.
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.
-
HIV Viral Rebound on Dolutegravir, Lopinavir, and Efavirenz: National Program Data Analysis From Ukraine. J Acquir Immune Defic Syndr. 2025 Aug 01; 99(4):395-404.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination. Cancer Lett. 2025 Mar 31; 613:217505.